Scarica l'app Stockscreener
11.71
2.72%
0.31
Dopo l'orario di chiusura:
11.63
-0.08
-0.68%
Precedente Chiudi:
$11.40
Aprire:
$11.4
Volume 24 ore:
4.67M
Relative Volume:
0.99
Capitalizzazione di mercato:
$1.26B
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-2.1369
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
+2.54%
1M Prestazione:
+1.91%
6M Prestazione:
+23.92%
1 anno Prestazione:
-45.84%
Intervallo 1D:
$11.34
$12.46
Intervallo di 1 settimana:
$11.06
$12.46
Portata 52W:
$5.90
$23.76
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.71 | 1.22B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Cathie Wood’s ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia - Investing.com
Panic Selling: Is Intellia Therapeutics Inc. benefiting from interest rate changesJuly 2025 Drop Watch & Verified High Yield Trade Plans - khodrobank.com
Signal strength of Intellia Therapeutics Inc. stock in tech scannersQuarterly Earnings Report & Safe Capital Growth Tips - Newser
Does Intellia Therapeutics Inc. stock have upside surprise potentialJuly 2025 Big Picture & Real-Time Buy Zone Alerts - khodrobank.com
Real time alert setup for Intellia Therapeutics Inc. performanceJuly 2025 Snapshot & High Accuracy Trade Alerts - Newser
How to forecast Intellia Therapeutics Inc. trends using time series2025 Support & Resistance & High Yield Stock Recommendations - Newser
Intellia Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Leading vs lagging indicators on Intellia Therapeutics Inc. performanceWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
What the charts say about Intellia Therapeutics Inc. todayPortfolio Value Report & Stepwise Swing Trade Plans - Newser
Tools to assess Intellia Therapeutics Inc.’s risk profileQuarterly Trade Report & Expert Verified Stock Movement Alerts - Newser
Why Intellia Therapeutics Inc. is moving today2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Multi asset correlation models including Intellia Therapeutics Inc.Profit Target & Daily Oversold Stock Bounce Ideas - Newser
Merger Talk: Is Intellia Therapeutics Inc. benefiting from interest rate changesEarnings Performance Report & Stepwise Trade Signal Implementation - khodrobank.com
Is Intellia Therapeutics Inc. stock reversal real or fakeJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
How hedge fund analytics apply to Intellia Therapeutics Inc. stockWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Will Intellia Therapeutics Inc. outperform tech stocksMarket Activity Report & Technical Buy Zone Confirmation - khodrobank.com
What’s next for Intellia Therapeutics Inc. stockMarket Sentiment Report & Real-Time Stock Price Movement Reports - khodrobank.com
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - TradingView
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Intellia Therapeutics Inc. Stock Flags Risk Zone in Volatility Index getLinesFromResByArray error: size == 0 - thegnnews.com
Aug Levels: What’s next for Intellia Therapeutics Inc. stockInsider Selling & Short-Term Trading Opportunity Alerts - khodrobank.com
Is Intellia Therapeutics Inc. building a consolidation base2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Pattern recognition hints at Intellia Therapeutics Inc. upside2025 Market WrapUp & High Accuracy Swing Entry Alerts - Newser
Why is Intellia Therapeutics Inc. stock going upJuly 2025 Update & High Accuracy Trade Signal Alerts - khodrobank.com
Is Intellia Therapeutics Inc. stock good for income investorsPortfolio Performance Report & Consistent Profit Trade Alerts - خودرو بانک
Insider Buy: Can Intellia Therapeutics Inc. navigate macro headwindsWeekly Trade Recap & Weekly Top Performers Watchlists - khodrobank.com
Why big players are pouring millions in THIS biotech stock - TradingView
Key metrics from Intellia Therapeutics Inc.’s quarterly dataJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
Intellia Therapeutics Inc. stock chart pattern explainedJuly 2025 Review & Weekly High Potential Stock Alerts - Newser
Applying sector rotation models to Intellia Therapeutics Inc.Trade Entry Report & Fast Entry High Yield Stock Tips - Newser
Intellia Therapeutics Inc. stock prediction for this week2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Using Python tools to backtest Intellia Therapeutics Inc. strategiesJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Chart based analysis of Intellia Therapeutics Inc. trendsJuly 2025 Patterns & Safe Entry Momentum Tips - Newser
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
Detecting support and resistance levels for Intellia Therapeutics Inc.Portfolio Risk Summary & Low Drawdown Trading Techniques - Newser
Is Intellia Therapeutics Inc. a candidate for recovery playJuly 2025 Institutional & Scalable Portfolio Growth Methods - Newser
Will Intellia Therapeutics Inc. bounce back from current support2025 Dividend Review & Risk Controlled Daily Trade Plans - Newser
Is Intellia Therapeutics Inc. trending in predictive chart modelsOil Prices & Free Technical Confirmation Trade Alerts - Newser
Cathie Wood Invests $4M in Intellia Therapeutics, Trims Stakes in Roku and DraftKings - AInvest
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):